Sridhar GR, Gumpeny L. Prospects and perils of ChatGPT in diabetes. World J Diabetes 2025; 16(3): 98408 [DOI: 10.4239/wjd.v16.i3.98408]
Corresponding Author of This Article
Gumpeny R Sridhar, Department of Endocrinology and Diabetes, Endocrine and Diabetes Centre, 15-12-15 Krishnanagar, Visakhapatnam 530002, Andhra Pradesh, India. sridharvizag@gmail.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Mar 15, 2025; 16(3): 98408 Published online Mar 15, 2025. doi: 10.4239/wjd.v16.i3.98408
Prospects and perils of ChatGPT in diabetes
Gumpeny R Sridhar, Lakshmi Gumpeny
Gumpeny R Sridhar, Department of Endocrinology and Diabetes, Endocrine and Diabetes Centre, Visakhapatnam 530002, Andhra Pradesh, India
Lakshmi Gumpeny, Department of Internal Medicine, Gayatri Vidya Parishad Institute of Healthcare & Medical Technology, Visakhapatnam 530048, Andhra Pradesh, India
Author contributions: Sridhar GR conceived the study and outlined a draft of the manuscript; Gumpeny L contributed to the writing and editing of the manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gumpeny R Sridhar, Department of Endocrinology and Diabetes, Endocrine and Diabetes Centre, 15-12-15 Krishnanagar, Visakhapatnam 530002, Andhra Pradesh, India. sridharvizag@gmail.com
Received: June 25, 2024 Revised: November 5, 2024 Accepted: December 3, 2024 Published online: March 15, 2025 Processing time: 209 Days and 18.1 Hours
Abstract
ChatGPT, a popular large language model developed by OpenAI, has the potential to transform the management of diabetes mellitus. It is a conversational artificial intelligence model trained on extensive datasets, although not specifically health-related. The development and core components of ChatGPT include neural networks and machine learning. Since the current model is not yet developed on diabetes-related datasets, it has limitations such as the risk of inaccuracies and the need for human supervision. Nevertheless, it has the potential to aid in patient engagement, medical education, and clinical decision support. In diabetes management, it can contribute to patient education, personalized dietary guidelines, and providing emotional support. Specifically, it is being tested in clinical scenarios such as assessment of obesity, screening for diabetic retinopathy, and provision of guidelines for the management of diabetic ketoacidosis. Ethical and legal considerations are essential before ChatGPT can be integrated into healthcare. Potential concerns relate to data privacy, accuracy of responses, and maintenance of the patient-doctor relationship. Ultimately, while ChatGPT and large language models hold immense potential to revolutionize diabetes care, one needs to weigh their limitations, ethical implications, and the need for human supervision. The integration promises a future of proactive, personalized, and patient-centric care in diabetes management.
Core Tip: ChatGPT, a large language model, was released to the public in late 2022. Its popularity lies in queries posted as conversation, eliciting human-like responses. Despite the available version being untrained in domain specific databases (e.g., diabetes), it is being increasingly used in diabetes. Once the accuracy improves, it promises to change the way diabetes is managed by aiding in patient education, dietary guidelines and providing emotional support. In addition, it has been used to assess a number of clinical situations and offer guidance in these areas.
